Cellular therapy (Frischzellentherapie)
injection · 1931–present
SHORT PITCH (AS SOLD)
Injection of fresh cells from organs of freshly killed lamb fetuses, claimed to restore the corresponding organs in the recipient and slow biological aging.
THE ACTUAL EVIDENCE
No controlled trial has demonstrated efficacy on any objective endpoint. The procedure's biological premise (organ-specific migration of foreign cells from a xenogeneic donor and integration into the recipient organ) is inconsistent with mammalian immunology. The practice is prohibited within recognized medicine in Switzerland and Germany. Reported clinical effects in the case literature are consistent with placebo, concurrent care, and selection bias in patient population.
PRACTITIONERS
INGREDIENTS
CASES
CLAIMS
- Injection of fetal sheep cells from a specific organ restores the function and structure of the corresponding aging organ in the recipient through migration and integration of the donor cells. refuted
- Cellular therapy as administered at Clinique La Prairie is safe; fresh fetal cells do not provoke meaningful immune rejection in human recipients and present no significant adverse-event risk. refuted
- Cellular therapy administered to a recipient of advanced age restores youthful function and reverses the visible and felt effects of biological aging. refuted
- Cellular therapy administered to Pope Pius XII in 1954 resolved his chronic gastric crisis and produced clinical improvement attributable to the treatment. refuted
SOURCES
- Introduction to Cellular Therapy (1960)
- Pope's Doctor (Time magazine feature on Paul Niehans) (1952)
- Swiss regulatory framework on fresh-cell therapy (1985)
NOTES
Cellular therapy, in the Niehans formulation, is the subcutaneous or intramuscular injection of macerated tissue from a freshly killed lamb fetus. Donor organs are selected to correspond to the recipient organ targeted for therapeutic effect. The protocol was developed at Clinique La Prairie in Clarens, Switzerland, beginning in 1931. The protocol was never demonstrated in a controlled trial and is now prohibited within recognized medicine in Switzerland and Germany. The practice is the direct historical ancestor of contemporary stem-cell tourism, plasma-based rejuvenation, and other biological-substance-transfer interventions sold to the wealthy on the premise that material from a young or fetal donor will rejuvenate the recipient.